Sign up
Pharma Capital

Imugene doses first patient in phase-two study of cancer vaccine

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong speaks to Proactive Investors about the pharma and biotech company’s HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.
The company recently dosed its first patient in the phase II study of the HER-Vaxx cancer vaccine.
The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein.

View full IMU profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.